Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 32,263 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $7.17, for a total transaction of $231,325.71. Following the completion of the sale, the insider directly owned 4,144,952 shares in the company, valued at $29,719,305.84. This trade represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total transaction of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Down 1.8%

Shares of TRDA opened at $7.17 on Friday. The stock has a market cap of $279.20 million, a price-to-earnings ratio of -1.81 and a beta of -0.25. Entrada Therapeutics, Inc. has a 12 month low of $5.02 and a 12 month high of $16.45. The company has a 50-day moving average price of $7.08 and a two-hundred day moving average price of $9.20.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Equities research analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TRDA. Baker BROS. Advisors LP increased its holdings in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares in the last quarter. 5AM Venture Management LLC acquired a new position in Entrada Therapeutics in the second quarter worth $29,854,949. GSA Capital Partners LLP acquired a new position in Entrada Therapeutics in the second quarter worth $648,000. Nantahala Capital Management LLC bought a new stake in shares of Entrada Therapeutics during the second quarter worth $2,212,232. Finally, BlackRock Inc. bought a new stake in shares of Entrada Therapeutics during the second quarter worth $19,013,000. Institutional investors own 86.39% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Guggenheim lowered their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Finally, Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.